Finance

Beta
Lists
SWOBY:OTCMKTS
Swedish Orphan Biovitrum ADR
$23.36
0.00%
(0.00) 1D
Jun 3, 3:03:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SWOBY...
Mkt. cap
159.19B
Avg. vol.
345.00
Volume
123.00
52-wk high
$29.32
52-wk low
$13.57
Beta
255.31
Shares outstanding
714.83M
No. of employees
2K
Mkt. cap
159.19B
Avg. vol.
345.00
Volume
123.00
52-wk high
$29.32
52-wk low
$13.57
Beta
255.31
Shares outstanding
714.83M
No. of employees
2K
News stories
From sources across the web
Profile
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden. In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
About Swedish Orphan Biovitrum ADR
CEOGuido Oelkers
Employees1.97K
Founded1939
Headquarters-
SectorBiotechnology
Websitesobi.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.18B
7.78B
7.82B
7.18B
Cost of goods sold
1.39B
1.56B
1.51B
1.70B
Cost of revenue
1.39B
1.56B
1.51B
1.70B
Research and development expenses
783.00M
754.00M
879.00M
948.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.74B
2.63B
2.93B
2.62B
Operating expense
3.53B
3.41B
3.75B
3.57B
Total operating expenses
4.93B
4.97B
5.26B
5.27B
Operating income
1.25B
2.80B
2.56B
1.91B
Other non operating income
-
1.00M
-25.00M
1.00M
EBT including unusual items
794.00M
-4.03B
2.17B
1.68B
EBT excluding unusual items
1.03B
2.64B
2.32B
1.72B
Income tax expense
160.00M
-1.13B
310.00M
363.00M
Effective tax rate
20.15%
28.12%
14.27%
21.59%
Other operating expenses
16.00M
26.00M
-57.00M
1.00M
Net income
636.00M
-2.89B
1.86B
1.32B
Net profit margin
10.30%
-37.22%
23.81%
18.35%
Earnings per share
2.36
6.05
5.65
4.07
Interest and investment income
-
-
22.00M
-
Interest expense
-216.00M
-168.00M
-156.00M
-173.00M
Net interest expenses
-216.00M
-168.00M
-134.00M
-173.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.14B
3.71B
3.13B
2.69B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer